NEW YORK, July 2, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Intellia Therapeutics, Inc. (NASDAQ: NTLA) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms. If you own NTLA please contact Justin Kuehn, Esq. by email at [email protected] or call (833) 672-0814. The consultation and case are free with n ...

Company Overview - Intellia is a genome editing company focused on developing CRISPR/Cas9-based therapeutics, with its lead candidate NTLA-2001 targeting transthyretin (ATTR) amyloidosis [3] - NTLA-2001 is part of a co-development and co-promotion agreement with Regeneron, where Regeneron shares 25% of the development costs and commercial profits [3][11] Recent Developments - The company appointed Edward Dulac as the new CFO, effective July 22, 2024, succeeding Glenn Goddard, who will step down on June 30, 2024 [1][9][10] - Intellia reported encouraging long-term data from the phase I portion of its study evaluating NTLA-2002 for hereditary angioedema (HAE) [4][13] Financial Performance - Year to date, shares of Intellia have declined by 24.8%, while the industry has seen a decline of 4.6% [2] - The company currently holds a Zacks Rank 3 (Hold) [6] Clinical Trials and Milestones - NTLA-2001 is being studied for two indications: ATTR amyloidosis with polyneuropathy and ATTR amyloidosis with cardiomyopathy, with the phase III MAGNITUDE study ongoing [12] - Several clinical milestones are expected later in the year, which may impact the company's growth trajectory [5]

CAMBRIDGE, Mass., June 26, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the appointment of Edward Dulac as Executive Vice President, Chief Financial Officer (CFO), and Treasurer, effective July 22, 2024. Mr. Dulac will succeed Glenn Goddard who will step down from his role effective June 30, 2024. "Ed's deep financial and business development experience at cli ...

CAMBRIDGE, Mass., June 26, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the appointment of Edward Dulac as Executive Vice President, Chief Financial Officer (CFO), and Treasurer, effective July 22, 2024. Mr. Dulac will succeed Glenn Goddard who will step down from his role effective June 30, 2024. Mr. Dulac is a highly accomplished biotechnology business leade ...

CAMBRIDGE, Mass., June 25, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today presented new data demonstrating for the first time the potential for redosing with an investigational, in vivo CRISPR/Cas9 genome editing therapy. These data from the ongoing Phase 1 study of NTLA-2001, a single-dose treatment in development for transthyretin (ATTR) amyloidosis, were presented at t ...

"Today's data showcase an exciting new platform advancement for Intellia and the field of gene editing. For the first time ever, we demonstrated that redosing with CRISPR, utilizing our proprietary, non-viral LNP-based delivery platform, enabled an additive pharmacodynamic effect on the target protein," said Intellia President and Chief Executive Officer John Leonard, M.D. "While redosing is not planned for the NTLA-2001 program for the treatment of transthyretin amyloidosis, part of our commitment to patie ...

Presentation Details In the dose-escalation portion of the Phase 1 study, the initial three patients received the lowest dose of 0.1 mg/kg and subsequently received a follow-on dose of 55 mg. These data will be the first-ever clinical data from patients redosed with an in vivo CRISPR-based gene editing candidate and provide insight on the safety and pharmacodynamic effect. While repeat dosing is not planned for the NTLA-2001 program for ATTR amyloidosis, a redosing option could be an important advantage of ...

If the data from the MAGNITUDE study is found to be positive, it will enable global regulatory filings for NTLA-2001. Image Source: Zacks Investment Research This apart, NTLA submitted a clinical trial application to initiate a first-in-human phase I study of NTLA-3001 in December 2023. The company plans to begin patient dosing later in 2024. Some better-ranked stocks in the healthcare sector are Acrivon Therapeutics, Inc. (ACRV) and Aligos Therapeutics, Inc. (ALGS) , each carrying a Zacks Rank #2 (Buy) at ...

Core Viewpoint - Intellia Therapeutics has appointed Brian Goff to its board of directors, bringing extensive experience in commercialization and operations within the biopharmaceutical industry, particularly in rare diseases [1][2][6]. Company Overview - Intellia Therapeutics, Inc. is a clinical-stage gene editing company focused on CRISPR-based therapies aimed at revolutionizing medicine. The company operates in vivo programs for precise gene editing within the human body and ex vivo programs for engineering human cells to treat cancer and autoimmune diseases [3]. Leadership Experience - Brian Goff has over three decades of experience in the biopharmaceutical sector, having held leadership roles at Agios Pharmaceuticals, Alexion Pharmaceuticals, Neurovance, and Baxalta. His expertise includes global commercialization and product launches for rare diseases [2][6]. Strategic Importance - The addition of Brian Goff to the board is seen as crucial for Intellia as it transitions from late-stage clinical development to commercialization of its CRISPR-based therapies for life-threatening diseases. His experience is expected to guide the company through this evolution [6].

CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the appointment of Brian Goff to its board of directors. Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. The company's in vivo programs use CRISPR to enable precise editing of diseas ...